| Treatment of IgA nephropathy: Recent advances and prospects |
12 |
| Prognosis and treatment of diabetic nephropathy: Recent advances and perspectives |
8 |
| Recent advances in the physiopathology of IgA nephropathy |
6 |
| Intracellular organelles in health and kidney disease |
5 |
| Complement inhibition in ANCA vasculitis |
4 |
| Aluminic intoxication in chronic hemodialysis. A diagnosis rarely evoked nowadays. Clinical case and review of the literature |
3 |
| Metabolic complications in chronic kidney disease: hyperphosphatemia, hyperkalemia and anemia |
3 |
| Identifying the specific causes of kidney allograft loss: A population-based study |
3 |
| Ifosphamide nephrotoxicity |
3 |
| Short-term effects with sucroferric oxyhydroxide in hemodialysis patients: Experience in NephroCare France |
2 |
| Human resources allocated to kidney transplantation in 2016 in France: A national survey |
2 |
| Management of Gitelman syndrome during pregnancy reporting 12 cases |
2 |
| Exceptional etiology of acute renal: Burkitt's lymphoma |
2 |
| Current insights about recurrence of glomerular diseases after renal transplantation |
2 |
| How to explain glomerular filtration rate decrease in intra-abdominal hypertension? |
2 |
| Kidney disease in cobalamin C deficiency |
2 |
| Prevention of infectious diseases in patients with chronic renal failure |
1 |
| Vancomycin nephrotoxicity: Frequency and mechanistic aspects |
1 |
| Proton pump inhibitors and kidney |
1 |
| Renal toxicity of high-dose methotrexate |
1 |
| Sodium, hypertension, chronic kidney diseases, and public health |
1 |
| Evaluation of living kidney donors renal function |
1 |
| Dietary control of metabolic acidosis in chronic kidney disease |
1 |
| Complications and treatment of mineral and bone disorders in chronic kidney disease |
1 |
| Renal toxicity of lithium |
1 |
| Interest of therapeutic drug monitoring of aminoglycosides administered by a monodose regimen |
1 |
| Renal hemosiderosis following mechanical hemolysis: An original case report |
1 |
| Middle-molecule uremic toxins: A renewed interest |
1 |
| Beta-blockers use from the general to the hemodialysis population |
1 |
| How to implement a complete apheresis program within a hemodialysis unit |
1 |
| Potential value of placental angiogenic factors as biomarkers in preeclampsia for clinical physicians |
1 |
| Clinical pharmacist and medication reconciliation in kidney transplantation |
1 |
| Socioeconomic inequalities and kidney transplantation |
1 |
| What do registries compared to clinical trials tell us? |
1 |
| Left ventricular hypertrophy in chronic hemodialysis patients at CNHU-HKM of Cotonou |
1 |
| Nephrogenic fibrosing dermatosis: From clinic to microscopy |
1 |
| Initiation of first dialysis and three months quality of life of patients with end stage renal disease in the French territories of Guadeloupe and Guyane |
1 |
| Screening for nephropathy in major sickle cell syndromes in patients monitored at the National Reference Center for Sickle Cell Disease in Niamey, Niger |
1 |
| PKHD1 mutations in autosomal recessive polycystic kidney disease (ARPKD): Genotype-phenotype correlations from a series of 308 cases to improve prenatal counselling |
1 |
| Effects of acoustic treatment of a dialysis room on the quality of life of patients |
1 |
| Cytomegalovirus infection in the first year after pediatric kidney transplantation |
1 |
| Treatment of AL amyloidosis |
1 |
| Epidemiology of acute renal failure |
1 |
| Calcific uremic arteriolopathy in hemodialysis patient, review of literature through five cases reports |
1 |
| Post-streptococcal glomerulonephritis in the south of Tunisia: A 12-year retrospective review |
1 |
| Description of immunosuppressive maintenance treatments post kidney transplant through the National System of Health Insurance |
1 |
| Plasmacytoma-like post-kidney-transplant lymphoproliferative disorder confined to renal allograft and urinary tract: A case report |
1 |
| Utilization of alfacalcidol and active vitamin D analogs in chronic kidney disease |
1 |
| Icodextrin: What arguments for and against its use as an osmotic agent in peritoneal dialysis |
1 |
| Discrepancies (and confluences) in perception between patients and nephrologists of chronic kidney disease impact on vital impetus in adults not undergoing hemodialysis: Results of the French MAEVA study |
1 |
